Airain Ltd’s Antares Pharma, Inc. ATRS Stock Holding History

Airain Ltd’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-27,402	Closed	-$78K	–	1100
2017 Q1	$78K	Buy	+27,402	New	+$65.9K	﹤0.01%	760
2013 Q4	–	Sell	-10,085	Closed	-$41K	–	734
2013 Q3	$41K	Buy	+10,085	New	+$44K	0.01%	450

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Airain Ltd's ATRS Position: Q2 2017 in Review

Airain Ltd sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 27,402 shares — an estimated $78K sold.

Airain Ltd first reported a position in ATRS in Q3 2013 and held it in 2 quarters. The position peaked at $78K in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

Airain Ltd reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Airain Ltd sold 27,402 Antares Pharma, Inc. shares in Q2 2017, an estimated $78K.
Airain Ltd first reported a position in Antares Pharma, Inc. in Q3 2013 and held it in 2 quarters.
Airain Ltd's Antares Pharma, Inc. position peaked at $78K in Q1 2017.
103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.